W. L. Gore & Associates enhances GORE® VIABAHN® Endoprosthesis portfolio with lower profile delivery

Improvements to large diameter devices include accessiblity through smaller sheaths while providing enhanced visualization under fluoroscopy

Sep 22, 2020

W. L. Gore & Associates Marks 20 Years of Improving and Extending Life for Patients with Liver Cirrhosis Complications

As liver disease prevalence grows worldwide, earlier TIPS intervention with the GORE® VIATORR® TIPS Endoprosthesis has proven to increase survival and to reduce complications of liver cirrhosis over conventional therapies.1

Aug 25, 2020

GORE Clinical Study Receives JVIR Editor’s Award For Outstanding Clinical Research Paper For 2019 From Journal of Vascular and Interventional Radiology

Analysis of the Gore REVISE Clinical Study data examined reinterventions and associated costs to maintain dialysis access in thrombosed and stenotic circuits.

May 1, 2020

Gore Receives CE Mark for the GORE® CARDIOFORM ASD Occluder for the Treatment of Atrial Septal Defects in Europe

CE Mark supported by data from the Gore ASSURED Clinical Study, demonstrating 100 percent closure success

Oct 2, 2019

W. L. Gore & Associates Hires John Laschinger, M.D., as Medical Products Division’s Cardiac Chief Medical Advisor

Gore furthers its commitment to patient-centered cardiac innovation

Sep 26, 2019

First patient enrolled in GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis pivotal study

U.S. pivotal study will determine safety and effectiveness of modular device designed to be the first completely off-the-shelf endovascular solution for aortic aneurysms involving the visceral branch vessels

Jul 18, 2019

GORE® ENFORM Biomaterial Earns Innovative Technology Designation from Vizient, Inc.

Designation recognizes products that bring improvements to the health care industry

Jul 17, 2019

First U.S. Patient Receives GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL

Data shows 100% successful deployment and no fractures at 30-day follow-up in European Registry

Jul 10, 2019

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

Data from the Gore ASSURED Clinical Study demonstrated 100 percent closure success at six months

Jun 4, 2019